News
07-15-2011, 05:10 AM
Amgen today announced that the European Commission (EC) has granted marketing authorization for XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.
More... (http://www.news-medical.net/news/20110715/EC-grants-marketing-authorization-for-Amgens-XGEVA-to-prevent-skeletal-related-events.aspx)
More... (http://www.news-medical.net/news/20110715/EC-grants-marketing-authorization-for-Amgens-XGEVA-to-prevent-skeletal-related-events.aspx)